Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).

Vaklavas C, Forero A.

BioDrugs. 2014 Jun;28(3):253-63. doi: 10.1007/s40259-014-0085-2. Review.

PMID:
24496926
2.

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthorne T, Yellin MJ, Davis TA, Vahdat LT.

J Clin Oncol. 2015 May 10;33(14):1609-19. doi: 10.1200/JCO.2014.56.2959. Epub 2015 Apr 6.

PMID:
25847941
3.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L.

J Clin Oncol. 2014 Nov 10;32(32):3619-25. doi: 10.1200/JCO.2013.52.5683. Epub 2014 Sep 29.

PMID:
25267761
4.

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.

Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R.

Pediatr Blood Cancer. 2016 Jan;63(1):32-8. doi: 10.1002/pbc.25688. Epub 2015 Aug 25.

PMID:
26305408
5.

The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.

Keir CH, Vahdat LT.

Expert Opin Biol Ther. 2012 Feb;12(2):259-63. doi: 10.1517/14712598.2012.642357. Epub 2012 Jan 9. Review.

PMID:
22229970
7.

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA.

Pediatr Blood Cancer. 2014 Oct;61(10):1816-21. doi: 10.1002/pbc.25099. Epub 2014 Jun 9.

8.

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Maric G, Rose AA, Annis MG, Siegel PM.

Onco Targets Ther. 2013 Jul 9;6:839-52. doi: 10.2147/OTT.S44906. Print 2013.

9.

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.

Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ.

Clin Cancer Res. 2006 Feb 15;12(4):1373-82.

10.

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.

Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM.

Clin Cancer Res. 2010 Apr 1;16(7):2147-56. doi: 10.1158/1078-0432.CCR-09-1611. Epub 2010 Mar 9.

11.

Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.

Qian X, Mills E, Torgov M, LaRochelle WJ, Jeffers M.

Mol Oncol. 2008 Jun;2(1):81-93. doi: 10.1016/j.molonc.2008.02.002. Epub 2008 Feb 16.

12.

Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.

Zhou LT, Liu FY, Li Y, Peng YM, Liu YH, Li J.

Neoplasma. 2012;59(1):1-5. doi: 10.4149/neo_2012_001. Review.

PMID:
22017590
13.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P.

J Clin Oncol. 2014 Nov 10;32(32):3659-66. doi: 10.1200/JCO.2013.54.8115. Epub 2014 Sep 29.

14.

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Rose AAN, Biondini M, Curiel R, Siegel PM.

Pharmacol Ther. 2017 May 22. pii: S0163-7258(17)30129-8. doi: 10.1016/j.pharmthera.2017.05.010. [Epub ahead of print] Review.

PMID:
28546082
15.

Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.

Okeley NM, Alley SC, Senter PD.

Hematol Oncol Clin North Am. 2014 Feb;28(1):13-25. doi: 10.1016/j.hoc.2013.10.009. Review.

PMID:
24287064
16.

GPNMB expression in uveal melanoma: a potential for targeted therapy.

Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P.

Melanoma Res. 2010 Jun;20(3):184-90. doi: 10.1097/CMR.0b013e3283364a08.

PMID:
20375921
17.

Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.

Deng S, Lin Z, Li W.

Curr Med Chem. 2017;24(23):2505-2527. doi: 10.2174/0929867324666170530092350. Review.

PMID:
28554322
18.

Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells.

Goldmacher VS, Kovtun YV.

Ther Deliv. 2011 Mar;2(3):397-416. Review.

PMID:
22834009
19.

Antibody-drug conjugates for cancer therapy.

Thomas A, Teicher BA, Hassan R.

Lancet Oncol. 2016 Jun;17(6):e254-e262. doi: 10.1016/S1470-2045(16)30030-4. Review.

PMID:
27299281
20.

Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.

Jackson D, Stover D.

Pharm Res. 2015 Nov;32(11):3458-69. doi: 10.1007/s11095-014-1536-7. Epub 2014 Oct 23. Review.

Supplemental Content

Support Center